Q. What is 'DengiAll', recently seen in news?
Answer:
Dengue vaccine
Notes: The tetravalent dengue vaccine, DengiAll, has entered phase-3 clinical trials. The trials are a collaboration between the Indian Council of Medical Research and Panacea Biotec. Dengue is a viral infection transmitted by infected female Aedes mosquitoes, also responsible for chikungunya and Zika. It is common in tropical and subtropical areas, mainly in urban and semi-urban regions. Dengue can lead to severe conditions like dengue hemorrhagic fever and dengue shock syndrome. Currently, there is no antiviral treatment or licensed vaccine for dengue in India.